Trimebutine
| Clinical data | |
|---|---|
| Trade names | Debridat, Recutin, Polybutin, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| Drug class | Various actions |
| ATC code | |
| Pharmacokinetic data | |
| Metabolites | nortrimebutine, N-didesmethyltrimebutine, 2-dimethylamino-2-phenylbutan-1-ol, 2-methylamino-2-phenylbutan-1-ol, 2-amino-2-phenylbutan-1-ol |
| Elimination half-life | 2.77 h (for oral dose 200 mg) |
| Excretion | renal, fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.354 |
| Chemical and physical data | |
| Formula | C22H29NO5 |
| Molar mass | 387.476 g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.1 ± 0.1 g/cm3 g/cm3 |
| Boiling point | 457.9 °C (856.2 °F) at 760 mmHg |
| |
| |
| | |
Trimebutine is a drug which is used in the treatment of irritable bowel syndrome and other gastrointestinal disorders. It is sometimes combined with simethicone as a combination drug. Trimebutine is formulated as a tablet or granules for oral suspension.